The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the US

03-Nov-2014 | Source : | Visits : 6791
REDWOOD CITY, Calif. - OncoMed Pharmaceuticals Inc. announced in a press release that it has been granted a new patent (US Patent No. 8,858,941) in the United States for OncoMed's anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and use of the bispecific antibody in the treatment of cancer. The new patent includes both composition-of-matter and method of treatment claims for the antibody. Related patent applications are pending in the United States, Europe, Japan, China and a number of other countries worldwide.

OncoMed's anti-DLL4/ant-VEGF bispecific antibody is one of many exciting programs in our preclinical development portfolio," said Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer. "The activity of anti-DLL4, with its robust anti-cancer stem cell and dysangiogenic properties, is expected to complement the anti-angiogenic activity of anti-VEGF to create a potent anti-tumor combination. We plan to initiate clinical trials of our novel bispecific antibody as early as late 2014 or early 2015."

OncoMed recently filed an Investigational New Drug (IND) application for its anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83), a novel humanized antibody generated using OncoMed's proprietary antibody technology platform. Preclinical studies suggest that the bispecific antibody may exhibit multiple mechanisms of action: (1) by targeting DLL4 and downregulating Notch pathway signaling, the antibody is expected to have an anti-CSC effect; and (2) by targeting DLL4 and VEGF, two central regulators of tumor angiogenesis, the antibody is expected to disrupt and inhibit tumor angiogenesis. In preclinical studies, the combined inhibition of DLL4 and VEGF has resulted in significant anti-tumor activity in a variety of patient-derived xenograft models.  OncoMed's anti-DLL4/anti-VEGF bispecific antibody is part of OncoMed's collaboration with Celgene Corporation.

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed has filed an Investigational New Drug (IND) application for its anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and plans to file an IND application for anti-RSPO3 (OMP-131R10) in early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com 
 
share



Related Articles